ILC Therapeutics Ltd Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2020

Location

Glasgow UK

Primary Industry

Biotechnology

About

Based in Lanarkshire, UK, and founded in 2020, ILC Therapeutics operates as a biotechnology company that develops novel peptide therapeutics intended to find a cure against COVID-19, ARDS, Oncology, Psoriasis, and Atopic Dermatitis. In September 2024, ILC Therapeutics Ltd raised EUR 2.5 million co-led by new investor Eos, returning investors Scottish Enterprise, and Medical Incubator Japan K.K. An individual investor also participated in the round. ILC Therapeutics develops a new class of interferon medicines called hybrid interferons that take features of natural interferon subtypes and combine them into one new hybrid interferon molecule that is designed to deliver enhanced efficacy and improved safety over a range of high-value therapeutic areas, enabling healthcare professionals to improve patient outcomes and find a cure against diseases. The company plans to use the September 2024 funding to assist its two lead assets, Alfacyte and Dermacyte, in its ongoing pre-clinical development as it approaches the clinic.

Current Investors

EOS Technology Investment Syndicate, Scottish Enterprise, Medical Incubator Japan

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Website

www.ilctherapeutics.com

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.